title: Electroporation-enhanced delivery of nucleic acid vaccines.
abstract: The naked delivery of nucleic acid vaccines is notoriously inefficient, and an enabling delivery technology is required to direct efficiently these constructs intracellularly. A delivery technology capable of enhancing nucleic acid uptake in both cells in tissues and in culture is electroporation (EP). EP is a physical delivery mechanism that increases the permeability of mammalian cell membranes and allows the trafficking of large macromolecules into the cell. EP has now been used extensively in the clinic and been shown to be an effective method to increase both the uptake of the construct and the breadth and magnitude of the resulting immune responses. Excitingly, 2014 saw the announcement of the first EP-enhanced DNA vaccine Phase II trial demonstrating clinical efficacy. This review seeks to introduce the reader to EP as a technology to enhance the delivery of DNA and RNA vaccines and highlight several published clinical trials using this delivery modality.
authors.affiliation: Inovio Pharmaceuticals Inc., 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, USA.
authors.forename: Kate E
authors.initials: KE
authors.lastname: Broderick
authors.forename: Laurent M
authors.initials: LM
authors.lastname: Humeau
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D018274:Electroporation / Q000379:methods*; D006801:Humans; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D019444:Vaccines, DNA
keywords: DNA vaccine; RNA vaccine; electroporation; electrotransfer